Men’s Health Daily Brief

PSA screening is a choice, not a diagnosis: a California men’s guide

California is expected to see about 32,610 prostate cancer diagnoses in 2026, but a PSA test is not an automatic yes-or-no answer. Age, risk, health and personal priorities belong in the decision.

September 9, 2026 · 4 min read

Older man discussing the benefits and limits of PSA screening with a physician in a Southern California clinic

California’s 2026 estimate gives the screening question real scale

The American Cancer Society estimates that California will have about 32,610 new prostate cancer cases and 4,210 deaths from the disease in 2026. Nationally, its estimate is 333,830 new cases and 36,320 deaths. Those numbers are model-based projections, rounded to the nearest 10—not a running count of diagnoses this year—and they do not tell any one man whether he has cancer. They do explain why the annual September focus on prostate cancer should lead to a careful health conversation instead of a vague promise to “get checked.”

A PSA test can start an evaluation; it cannot make the diagnosis

Prostate-specific antigen is made by normal prostate cells as well as cancer cells. A PSA blood test can be used for screening in a person without symptoms, to investigate symptoms or to monitor someone already treated for prostate cancer. A higher result is not a cancer diagnosis. Benign prostate enlargement, inflammation or infection can also raise PSA, and no single number cleanly separates cancer from a noncancerous condition. That is why a lab value has to be read alongside age, health history, medicines, prior results and the reason the test was ordered.

The national recommendations do not begin with one universal birthday

The U.S. Preventive Services Task Force says men ages 55 to 69 should make an individual decision about periodic PSA screening after discussing possible benefits and harms with a clinician; it recommends against routine PSA screening at age 70 and older. The American Cancer Society uses earlier discussion points: age 50 for men at average risk who are expected to live at least 10 more years, age 45 for Black or African American men and men with a father or brother diagnosed before 65, and age 40 for men with more than one first-degree relative diagnosed early. These are conversation thresholds from different organizations, not automatic testing orders.

Risk can move the conversation earlier

Age is the most common risk factor, according to the Centers for Disease Control and Prevention. CDC also identifies Black or African American men and men with a family history of prostate cancer as groups at higher risk of developing or dying from the disease. A useful family history reaches beyond “Did my father have it?” Ask which close relatives had prostate, breast, ovarian or pancreatic cancer, how old they were at diagnosis and whether a known inherited gene change is present in the family. Bring the details to a licensed clinician; a family pattern may matter, but an online risk list cannot calculate a personal diagnosis.

The real tradeoff is early detection versus avoidable harm

PSA screening may find a dangerous cancer earlier, before it spreads, and trials show a small reduction in prostate cancer deaths over time. It can also produce a false-positive result, lead to biopsy complications or detect a slow-growing cancer that would never have caused symptoms. Treating an overdiagnosed cancer can expose someone to urinary, bowel and sexual side effects without extending his life. The decision therefore depends partly on how a person values a possible earlier finding against the chance of testing, procedures and treatment that may not help him. Neither concern should be dismissed.

One elevated result does not always send a patient straight to biopsy

For a person without symptoms, the National Cancer Institute says a clinician may repeat an abnormal PSA test in six to eight weeks before deciding what comes next. A persistent elevation can lead to closer observation, another blood or urine test, imaging such as MRI, or biopsy depending on the overall risk. Some temporary factors—including prostate inflammation, recent prostate procedures, vigorous cycling and ejaculation—can affect PSA, while finasteride and dutasteride can lower it. Do not stop a medicine or invent a preparation rule from a search result; tell the ordering clinician about medicines, supplements, symptoms and recent activities and follow that office’s instructions.

Symptoms need evaluation even when a screening calendar says “later”

Screening is for people without symptoms. Trouble starting urination, a weak or interrupted stream, frequent urination, blood in urine or semen, painful ejaculation, or persistent pain in the back, hips or pelvis can have causes other than prostate cancer, including benign prostate enlargement or infection. They still deserve a clinical evaluation instead of waiting for the next routine screening discussion. Seek urgent care for an inability to urinate, severe or rapidly worsening pain, heavy bleeding, fainting or another acute danger; call 911 for a life-threatening emergency.

Bring five concrete questions to the appointment

Ask: What is my risk based on age, family history and ancestry? What benefit is realistic for someone with my health and life expectancy? What can raise or lower my PSA before the test? If the result is elevated, will we repeat it before another procedure? And what would make imaging, biopsy or active surveillance appropriate? Write down the answer and the follow-up interval. This article is educational, not personal medical advice. NOCTI and independent massage or wellness providers do not screen for, diagnose or treat prostate cancer and should never replace primary care, urology or emergency services.

Sources

Find men's massage near you

Compare local providers privately and contact the professional you choose directly.

Search NOCTI